Related Experiment Video
Updated: Apr 29, 2026
A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate NMDA Receptor in Blood
Published on: January 9, 2018
[N-methyl-D-aspartate receptor antibody encephalitis: value of immunomodulatory therapy]
L Le Moigno1, D Ternant2, G Paintaud3
1Service de neuropédiatrie, unité Inserm U930, hôpital d'Enfants Gatien de Clocheville, université de Tours, CHU de Tours, 49, boulevard Béranger, 37044 Tours cedex 01, France.
Insights
Anti-N-methyl-D-aspartate receptor (NMDA-R) encephalitis is a severe but reversible condition in children. Early diagnosis and treatment with rituximab can lead to recovery, even with rapid B-cell repopulation.
Area of Science:
- Pediatric Neurology
- Neuroimmunology
- Autoimmune Encephalitis
Background:
- Anti-N-methyl-D-aspartate receptor (NMDA-R) encephalitis is underdiagnosed in children, posing risks to vital and cognitive prognoses.
- Immunomodulatory treatments, including rituximab, show promise but require further investigation into their mechanisms.
Observation:
- A 6-year-old girl presented with status epilepticus, behavioral changes, and orofacial dyskinesia.
- Diagnosis was confirmed by NMDA-R antibodies in CSF; initial treatments (IVIg, plasma exchange) were followed by rituximab.
- The patient recovered with rituximab despite rapid B-cell pool recovery.
Findings:
- Rituximab treatment led to a cure in a pediatric case of anti-NMDA-R encephalitis.
- Successful treatment occurred despite an unusually rapid recovery of B-cells post-rituximab.
Implications:
- Early diagnosis and treatment are crucial for potentially reversible outcomes in pediatric NMDA-R encephalitis.
- Rituximab appears effective, highlighting the need for further research into its action in childhood autoimmune neurological disorders.
- Immunological monitoring is essential for understanding treatment mechanisms in pediatric autoimmune neurological diseases.
Introduction:
Anti-N-methyl-D-aspartate receptor (NMDA-R) encephalitis is little known to pediatricians and likely underdiagnosed. The child's vital and cognitive prognosis is at stake. The use of immunomodulatory drugs, such as rituximab has led to spectacular results, but many questions remain about its mode of action in this type of pathology.
Case Report:
We report the case of a 6-year-old girl with no medical history, admitted for status epilepticus preceded by behavior symptoms and sleep disorders. Gradually, the child became bedridden, mute, and animated by predominantly orofacial dyskinesia. Examinations were normal (cerebrospinal fluid [CSF] analysis, brain MRI). The diagnosis was established by the presence of NMDA-R antibodies in the CSF. After exclusion of a tumor-associated syndrome, treatment was started initially by intravenous immunoglobulins, then by plasma exchange, and finally rituximab. The patient was cured with rituximab despite an unusually early recovery of the B-cell pool.
Discussion:
Anti-N-methyl-D-aspartate receptor (NMDA-R) encephalitis is a severe but potentially reversible neurologic disorder only recently described, even in childhood. It may be reversible without sequelae if diagnosed and treated early. The use of immunomodulatory therapy, such as rituximab seemingly improves the outcome. Immunological monitoring is needed to better understand its mechanism of action in autoimmune diseases of the nervous system in childhood.
More Related Videos
10:19High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
Published on: November 23, 2013
06:19Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
Related Concept Videos
01:26Encephalitis ll: Pathophysiology
01:19Encephalitis l: Introduction
01:14Antiepileptic Drugs: Glutamate Antagonists
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists